Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Chief Commercial Officer | February 20, 2025 | February 20, 2025 |
| Autolus Therapeutics plcAUTL · Entity 1933 | U.S. CCO & Country Gen Manager | September 01, 2026 | September 03, 2026 |
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Chief Commercial Officer | July 03, 2023 | July 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date February 20, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.10 · Expires 2035-02-20 | Direct | 1,612,032 |
Reported balance
After 2025-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-20 · Grant · Acquired 1,612,032 · Balance 1,612,032 F1: The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2: Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029. |
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,074,696 |
Reported balance
After 2025-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-20 · Grant · Acquired 1,074,696 · Balance 1,074,696 F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4: Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029. F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2: Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029.
F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4: Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029.
F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
Autolus Therapeutics plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 13,287 |
Ending reported balance
After 2026-09-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 20,000 · Balance 20,000 Row 2 · 2026-09-02 · Sale · Disposed 6,713 · Balance 13,287 |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 60,000 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Disposed 20,000 · Balance 60,000 F1: Each RSU represents a contingent right to receive one Issuer American Depositary Share. F2: The restricted share units ("RSUs") vest in four equal annual installments commencing on September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one Issuer American Depositary Share.
F2: The restricted share units ("RSUs") vest in four equal annual installments commencing on September 1, 2026.
Kalaris Therapeutics, Inc.
Report date July 03, 2023 · Filed July 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 147,000 |
Reported balance
After 2023-07-03 transaction · row 1
1 source rowRow 1 · 2023-07-03 · Grant · Acquired 147,000 · Balance 147,000 F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2033-07-03 | Direct | 273,000 |
Reported balance
After 2023-07-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-03 · Grant · Acquired 273,000 · Balance 273,000 F2: 25% of this option shall vest and become exercisable on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.
F2: 25% of this option shall vest and become exercisable on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 20:36 UTC | Autolus Therapeutics plc AUTL · Entity 1933 | SaleAmerican Depositary Shares | 6,713 | $2.34 | $15,681.57 |
DisclosureSEC source: 0001730463-26-000131 · form4.xml · nonDerivative · entry 2 Piccina Cintia · CIK 0001907199 · U.S. CCO & Country Gen Manager 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,287 Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:36 UTC | Autolus Therapeutics plc AUTL · Entity 1933 | Exercise / conversionRestricted Share Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001730463-26-000131 · form4.xml · derivative · entry 3 Piccina Cintia · CIK 0001907199 · U.S. CCO & Country Gen Manager 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: American Depositary Shares · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one Issuer American Depositary Share. F2 · derivative.exercise_date: The restricted share units ("RSUs") vest in four equal annual installments commencing on September 1, 2026. F2 · derivative.expiration_date: The restricted share units ("RSUs") vest in four equal annual installments commencing on September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:36 UTC | Autolus Therapeutics plc AUTL · Entity 1933 | Exercise / conversionAmerican Depositary Shares | 20,000 | $2.35 | $47,000.00 |
DisclosureSEC source: 0001730463-26-000131 · form4.xml · nonDerivative · entry 1 Piccina Cintia · CIK 0001907199 · U.S. CCO & Country Gen Manager 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2025 Filed Feb 20, 2025 22:32 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,074,696 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015742 · tm257186-3_4seq1.xml · derivative · entry 2 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,074,696 Underlying: Ordinary Shares · 1,074,696 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| February 20, 2025 Filed Feb 20, 2025 22:32 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,612,032 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001104659-25-015742 · tm257186-3_4seq1.xml · derivative · entry 1 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,612,032 Underlying: Ordinary Shares · 1,612,032 shares Expires 2035-02-20 F1 · derivative.exercise_price: The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029. Read SEC document |
| January 15, 2025 Filed Jan 15, 2025 21:18 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 12,991 | $0.57 | $7,467.23 |
DisclosureSEC source: 0001104659-25-003774 · tm253441-4_4seq1.xml · nonDerivative · entry 1 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,421 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 25% of the remaining balance of an RSU-style share option covering ordinary shares of the Issuer granted on March 18, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.57 to $0.595, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 92,652 ADSs and RSU-style options and other options covering an aggregate of 6,779,928 ordinary shares of the Issuer. Read SEC document |
| June 18, 2024 Filed Jun 18, 2024 21:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 24,531 | $0.93 | $22,813.83 |
DisclosureSEC source: 0001104659-24-072874 · tm2417532-1_4seq1.xml · nonDerivative · entry 1 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,293 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately one third of an RSU-style share option covering ordinary shares of the Issuer granted on March 18, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is the sale price per ADS. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 54,359 ADSs and RSU-style options and other options covering an aggregate of 6,968,400 ordinary shares of the Issuer. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 21:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,130,832 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-035619 · tm249079d1_4seq1.xml · derivative · entry 2 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,130,832 Underlying: Ordinary Shares · 1,130,832 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.273980 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 376,944 Ordinary Shares on June 18, 2024 and will be exercisable as to the remainder in installments of 188,472 Ordinary Shares on January 15, 2025, January 15, 2026, January 15, 2027 and January 15, 2028. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 21:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 5,088,864 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001104659-24-035619 · tm249079d1_4seq1.xml · derivative · entry 1 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,088,864 Underlying: Ordinary Shares · 5,088,864 shares Expires 2034-03-18 F1 · derivative.exercise_price: The exercise price was converted from GBP0.19 based on an exchange rate of $U.S. 1.273980 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 1,679,325 Ordinary Shares on March 18, 2024 and will be exercisable as to the remainder in monthly installments of 94,704 Ordinary Shares on the last day of each month from April 18, 2024 through February 18, 2027 and 94,899 Ordinary Shares on March 18, 2027. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 273,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001209191-23-041171 · doc4.xml · derivative · entry 2 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,000 Underlying: Common Stock · 273,000 shares Expires 2033-07-03 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 147,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041171 · doc4.xml · nonDerivative · entry 1 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,000 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 31, 2023 Filed Feb 1, 2023 02:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 11,890 | $1.87 | $22,229.54 |
DisclosureSEC source: 0001104659-23-008858 · tm231655-21_4seq1.xml · nonDerivative · entry 1 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,535 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 31, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.85 to $1.895, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 34,824 ADSs and RSU-style options and other options covering an aggregate of 5,845,530 ordinary shares of the Issuer. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 02:02 UTC | Adaptimmune Therapeutics PLC ADAP] · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 181,560 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004370 · tm231655-10_4seq1.xml · derivative · entry 3 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,560 Underlying: Ordinary Shares · 181,560 shares Expires 2025-03-15 F6 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 02:02 UTC | Adaptimmune Therapeutics PLC ADAP] · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 314,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004370 · tm231655-10_4seq1.xml · derivative · entry 2 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,256 Underlying: Ordinary Shares · 314,256 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 02:02 UTC | Adaptimmune Therapeutics PLC ADAP] · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,407,072 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001104659-23-004370 · tm231655-10_4seq1.xml · derivative · entry 1 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,072 Underlying: Ordinary Shares · 1,407,072 shares Expires 2033-01-17 F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 01:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 21,040 | $1.77 | $37,314.44 |
DisclosureSEC source: 0001104659-22-084893 · tm2222258d1_4seq.xml · nonDerivative · entry 1 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,824 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 31, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.7642 to $1.7808, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 4,131,192 ordinary shares of the Issuer. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 02:05 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 335,184 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-009932 · tm221700-20_4seq1.xml · derivative · entry 3 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,184 Underlying: Ordinary Shares · 335,184 shares Expires 2023-03-15 F6 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 02:05 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 754,200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-009932 · tm221700-20_4seq1.xml · derivative · entry 2 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 754,200 Underlying: Ordinary Shares · 754,200 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 188,550 Ordinary Shares on January 31, 2023 and will be exercisable as to the remainder in annual installments of 188,550 Ordinary Shares on the thirty-first of each January from January 31, 2024 through January 31, 2026. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 02:05 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 3,376,992 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001104659-22-009932 · tm221700-20_4seq1.xml · derivative · entry 1 Piccina Cintia · CIK 0001907199 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,376,992 Underlying: Ordinary Shares · 3,376,992 shares Expires 2032-01-31 F1 · derivative.exercise_price: The exercise price was converted from GBP0.33 based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 844,248 Ordinary Shares on January 31, 2023 and will be exercisable as to the remainder in monthly installments of 70,350 Ordinary Shares on the last day of each month from February 28, 2023 through December 31, 2025 and 70,494 Ordinary Shares on January 31, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.